

Addendum: A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer

Sewanti Limaye¹, Prashant Kumar^{2,3,4}, Ramya Pragya¹, Janani Sambath^{3,4}, Darshana Patil², Ajay Srinivasan², Sachin Apurva², Navin Srivastava², Sanket Patil², Revati Patil², Vineet Datta², Dadasaheb Akolkar² and Rajan Datar²

¹Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India

²Datar Cancer Genetics Limited, Nasik, Maharashtra, India

³Institute of Bioinformatics, International Technology Park, Bangalore, Karnataka, India

⁴Manipal Academy of Higher Education, Manipal, Karnataka, India

Published: August 04, 2022

Copyright: © 2022 Limaye et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Consent was added to this article: The patient provided consent (by signing on a consent document) at the time of tumor tissue and blood sample collection stating willingness to:

- a. Provide the required sample for tumor molecular profiling.
- b. Research use of deidentified data including publication of (deidentified) findings.

Original article: Oncotarget. 2020; 11:4358–4363. <https://doi.org/10.18632/oncotarget.27809>